Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
29 studies found for:    " November 21, 2011":" December 21, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" November 21, 2011":" December 21, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting
Has Results
Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TDF;   Drug: E/C/F/TAF Placebo;   Drug: E/C/F/TAF;   Drug: E/C/F/TDF Placebo
2 Completed
Has Results
Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: NNRTI;   Drug: FTC/TDF;   Drug: Stribild
3 Completed Telephone-delivered Behavioral Interventions to Reduce Risky Sexual Behavior in HIV-positive Late Middle-age and Older Adults
Condition: Unsafe Sex
Interventions: Behavioral: 1-session of telephone-administered motivational interviewing;   Behavioral: 4-session telephone-administered motivational interviewing
4 Completed Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
Condition: HIV Infections
Interventions: Biological: HIV-MAG (3,000mcg);   Biological: GENEVAX® IL-12 (100mcg);   Biological: GENEVAX® IL-12 (1000mcg);   Biological: Ad35-GRIN/ENV
5 Completed Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence
Condition: HIV Infection
Interventions: Drug: Immediate ARV treatment initiation with TDF/FTC/EFV;   Other: South African recommendation guided ARV (TDF/FTC/EFV) initiation
6 Recruiting Use of Incentives to Retain Drug Users in HIV Therapy
Condition: HIV Infection
Intervention: Other: monetary reinforcer
7 Completed Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries
Conditions: Partner HIV Testing;   Couple HIV Counseling;   Couple Communication;   HIV Incidence
Intervention: Behavioral: Couple-oriented post-test HIV counseling
8 Active, not recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
9 Withdrawn Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
10 Completed
Has Results
Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
11 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
12 Active, not recruiting Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Conditions: Tobacco Cessation;   HIV;   AIDS
Interventions: Behavioral: Treatment as usual;   Behavioral: AIR (Aspirations, Inspiration, Respiration)
13 Completed Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Conditions: Human Immunodeficiency Virus Infection;   Sexually Transmitted Diseases
Interventions: Behavioral: Men Making a Difference HIV/STD Risk Reduction Intervention;   Behavioral: Health Promotion Control
14 Completed American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
Condition: HIV/AIDS-associated Fatigue
Interventions: Drug: American ginseng;   Dietary Supplement: Placebo for American ginseng
15 Recruiting Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management
Condition: HIV
Intervention: Behavioral: VIH-TAVIE
16 Completed WHC+ (Women's Health CoOp PLUS)
Conditions: HIV;   Sexual Risk;   Sexually Transmitted Diseases;   Substance Abuse;   Violence;   Victimization
Interventions: Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC);   Biological: Test, Treat, Retain(TTR) only
17 Completed Early HIV Therapy in Patients With High CD4 Cell Counts
Condition: HIV
Interventions: Drug: Standard ART;   Drug: Study-Provided ART
18 Completed Antiretroviral Drug Interaction Study in Volunteers With HIV
Conditions: HIV;   PCP;   Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily;   Drug: Atovaquone 1500 mg twice daily
19 Completed Men of African American Legacy Empowering Self
Condition: HIV
Interventions: Behavioral: Men of African American Legacy Empowering Self;   Behavioral: Standard HIV Education & Risk Reduction
20 Terminated Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Indicates status has not been verified in more than two years